FTDI
TBPH icon

First Trust Direct Indexing’s Theravance Biopharma TBPH Stock Holding History

First Trust Direct Indexing’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,236
Closed -$93K – 928
2020
Q4 		$93K Buy
+5,236
New +$94K 0.03% 532

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

First Trust Direct Indexing's TBPH Position: Q1 2021 in Review

First Trust Direct Indexing sold out of Theravance Biopharma (TBPH) in Q1 2021, closing a stake of 5,236 shares — an estimated $93K sold.

First Trust Direct Indexing first reported a position in TBPH in Q4 2020 and held it in 1 quarter. The position peaked at $93K in Q4 2020. 107 funds tracked by Wall St. Rank hold TBPH as of Q1 2021.

  • First Trust Direct Indexing reported no remaining Theravance Biopharma position as of Q1 2021 after selling out during the quarter.
  • First Trust Direct Indexing sold 5,236 Theravance Biopharma shares in Q1 2021, an estimated $93K.
  • First Trust Direct Indexing first reported a position in Theravance Biopharma in Q4 2020 and held it in 1 quarter.
  • First Trust Direct Indexing's Theravance Biopharma position peaked at $93K in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2021.

Based on First Trust Direct Indexing's 13F filing for Q1 2021, filed 14 Apr 2021.